Immune System News and Research

RSS

Scientists discover mechanism used by A20 protein to combat inflammation

Scientists affiliated with VIB and UGent have discovered a mechanism used by the protein A20 to combat inflammation. This could be a very important point of focus in the search for a treatment for autoimmune diseases such as Rheumatoid Arthritis, in which the patient suffers from chronic, uncontrolled inflammation.

10 Oct 2012

Roitt's Essential Immunology receives BMA Book of the Year Award

John Wiley & Sons, Inc., today announced that Roitt's Essential Immunology, 12th Edition, has won the prestigious British Medical Association (BMA) Book of the Year Award.

10 Oct 2012

CRI, MedImmune partner to advance cancer immunotherapy research

The Cancer Research Institute (CRI), the Ludwig Institute for Cancer Research and MedImmune, the global biologics arm of AstraZeneca, today announced that they have signed a collaboration agreement to advance the research of immunotherapy in cancer.

10 Oct 2012

GSK, Aeras to advance clinical development of TB vaccine

Aeras announces that it has signed an agreement with GlaxoSmithKline Vaccines, S.A. (GSK) to jointly advance the clinical development of an investigational tuberculosis (TB) vaccine containing GSK's proprietary M72 antigen and AS01E adjuvant.

10 Oct 2012

T2R38 taste receptor regulates immune defense of the human upper airway

The immune system protects the upper respiratory tract from bacterial infections, but the cues that alert the immune system to the presence of bacteria are not known. In this issue of the Journal of Clinical Investigation, researchers led by Noam Cohen at the University of Pennsylvania demonstrated that the bitter taste receptor T2R38 regulates the immune defense of the human upper airway.

9 Oct 2012

New data from Genzyme's AUBAGIO and LEMTRADA clinical trials to be presented at ECTRIMS

Genzyme, a Sanofi company, announced today new data from Genzyme's clinical development programs for AUBAGIO (teriflunomide) and LEMTRADATM (alemtuzumab) will be presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Lyon, France, October 10-13.

9 Oct 2012

Study sheds light on fundamental cellular process

Scientists at the Gladstone Institutes have mapped the precise frequency by which genes get turned on across the human genome, providing new insight into the most fundamental of cellular processes-and revealing new clues as to what happens when this process goes awry.

9 Oct 2012

Scientists discover how protein deficiency may be linked to frontotemporal dementia

Using animal models, scientists at the Gladstone Institutes have discovered how a protein deficiency may be linked to frontotemporal dementia (FTD)-a form of early-onset dementia that is similar to Alzheimer's disease. These results lay the foundation for therapies that one day may benefit those who suffer from this and related diseases that wreak havoc on the brain.

9 Oct 2012

New blood test can read genetic changes in prostate cancer

Scientists have designed a blood test that reads genetic changes like a barcode - and can pick out aggressive prostate cancers by their particular pattern of gene activity.

9 Oct 2012

Fertility treatment may increase MS disease activity

Findings published in Annals of Neurology suggest that assisted reproduction technology treatment increases multiple sclerosis disease activity.

8 Oct 2012

Liquorice-based nanotech material for sterilizing medical devices

A nanotech material containing an extract from liquorice can be used to sterilize and protect medical devices and implants which include biological components, and protects these functional bio-components during the sterilization process.

8 Oct 2012

NFKB1 gene variant may reduce risk of lung cancer

A variant in a gene involved with inflammation and the immune response is linked with a decreased risk of lung cancer. That is the finding of an analysis published early online in CANCER, a peer-reviewed journal of the American Cancer Society. The results add to the growing body of literature implicating these processes in the development of lung cancer.

8 Oct 2012

CytoDyn announces update on feline immunodeficiency virus therapeutic antibody program

CytoDyn Inc., a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, announced today that it is presenting an update on its Feline Immunodeficiency Virus (FIV) therapeutic antibody program at the 19th West Coast Retrovirus meeting in Palm Springs, California.

8 Oct 2012

FDA clears Fenwal's new plasma products

Fenwal Inc., a global leader specializing in separation technologies for blood and cell collection and therapy, announced today it has received clearance from the U.S. Food and Drug Administration for two new indications for collection of plasma products on the Fenwal Alyx and Amicus systems.

8 Oct 2012

FMCNA urges dialysis patients to get flu shots

With flu season just around the corner, Fresenius Medical Care North America (FMCNA), the nation's leading network of dialysis facilities, is urging dialysis patients to get flu shots to protect themselves against this common infectious disease. In October, FMCNA will begin offering at no cost to all of its dialysis patients and staff, flu vaccinations, which protect against both seasonal flu and H1N1 swine flu.

6 Oct 2012

NIH awards $2.1M grant to study possible ways to fight cancer

A professor with the University of Houston Cullen College of Engineering has won a $2.1 million grant to study the best ways to modify human immune cells to fight against cancer.

6 Oct 2012

Study links PI3Kgamma molecule with multiple sclerosis

A University of Adelaide researcher has published results that suggest a possible new mechanism to control multiple sclerosis (MS).

5 Oct 2012

New prototype mouse model duplicates the human response in rheumatoid arthritis

Researchers at Northwestern University Feinberg School of Medicine have developed the first animal model that duplicates the human response in rheumatoid arthritis (RA), an important step that may enable scientists to discover better medicines to treat the disease.

5 Oct 2012

Patients with eye diseases can benefit from ArtCornea

Blindness is often caused by corneal diseases. The established treatment is a corneal transplant, but in many cases this is not possible and donor corneas are often hard to come by. In the future, an artificial cornea could make up for this deficiency and save the vision of those affected.

5 Oct 2012

Transplant recipients and lymphoma patients far likelier to develop melanoma

Melanoma is on the rise nationally, and transplant recipients and lymphoma patients are far likelier than the average person to get that form of skin cancer and to die from it, a Mayo Clinic review has found.

5 Oct 2012